Femasys (NASDAQ:FEMY) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of Femasys (NASDAQ:FEMY) from a sell rating to a strong sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

FEMY has been the topic of a number of other research reports. Maxim Group decreased their target price on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Weiss Ratings downgraded Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Finally, Lake Street Capital cut their price target on Femasys to $10.00 and set a “buy” rating for the company in a report on Tuesday, August 18th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.00.

Femasys Price Performance

Femasys stock opened at $1.32 on Friday. The stock has a market capitalization of $11.06 million, a P/E ratio of -0.37 and a beta of -2.16. Femasys has a 12-month low of $1.29 and a 12-month high of $22.20. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.14 and a quick ratio of 0.55. The firm’s 50-day moving average is $2.25 and its two-hundred day moving average is $6.13.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings data on Friday, August 14th. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). The firm had revenue of $0.33 million during the quarter, compared to analyst estimates of $0.73 million. Femasys had a negative net margin of 534.36% and a negative return on equity of 225.97%.

Insider Transactions at Femasys

In other Femasys news, CFO Dov Elefant purchased 15,625 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were purchased at an average cost of $3.20 per share, with a total value of $50,000.00. Following the purchase, the chief financial officer owned 15,625 shares in the company, valued at approximately $50,000. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Kathy Lee-Sepsick purchased 15,625 shares of the stock in a transaction on Friday, August 7th. The stock was acquired at an average price of $3.20 per share, with a total value of $50,000.00. Following the acquisition, the chief executive officer directly owned 15,625 shares in the company, valued at $50,000. This trade represents a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 38,750 shares of company stock worth $124,000. 7.75% of the stock is owned by corporate insiders.

Femasys Company Profile

Femasys Inc is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures.

Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.